Close Menu CLOSE



Nucleic Acid Transfection Kits for Primary Neurons


• 95% cell transfection efficiency
• No observed cytotoxicity
• Gene knockdown via siRNA expression
in vitro and in vivo applications
• Non viral transfection




• siRNA transfection for gene knockdown via RNAi both in vitro and in vivo

Top Right: Enriched (>90%) E18 primary rat cortical neurons treated at DIV12 with Neuro9 siRNA against HPRT. HPRT mRNA assayed by qPCR 48h post-treatment. *** P < 0.001

Middle Right: Enriched (>90%) E18 primary rat cortical neurons treated at DIV7 with Neuro9 siRNA against HPRT for 48 hours. Cell viability assayed using PrestoBlue.

Bottom Right: Primary rat neurons were treated at various stages of maturiny with Neuro9 siRNA against PTEN. Neuro9 is well tolerated, and can be applied at DIV ≥ 2. This flexibilty opens doors to new experimental possibilities. *** P < 0.001

90% knockdown in 95% of Cells

No Observable Toxicity

Mediate Gene Expression as Early as DIV2

Neuro9 in vitro cell culture and transfection
siRNA : > 95% Cellular Transfection Efficicency
Spark Transfection Kit Workflow
Images: Fluorescently labeled Neuro9 (red) is used to observe uptake by MAP2+ neurons (green).
Plot: Flow cytometry indicates Neuro9 uptake in >95% of cells

Neuro9 in vivo
siRNA : > 95% Transfection Efficicency
Neuro9 (red) was locally injected into rat somatosensory cortex. Brains were removed 5 days later, sliced and imaged. Calcein-AM dye (green) indicates neurons were alive when imaged. Western blots from samples 1mm from the injection site exhibit significant knockdown of target gene PTEN compared to “control” samples taken from the opposite hemisphere and samples treated with Luc siRNA.

Neuro9 Spark
Transfection Kits
Kit TypeEncapsulatesTreats (wells of 24 well plate)DetailsCatalogue
siRNA2 nmol (2x)50Spec SheetNWT0001
siRNA5 nmol100Spec SheetNWT0002

Neuro9 Benchtop
Transfection Kits
Kit TypeEncapsulatesTreats (wells of 24 well plate)DetailsCatalogue
siRNA0.5 mg15Spec SheetNWT0001
siRNA2 mg20Spec SheetNWT0002

Get Started

To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.

Get in Touch

Resource Center


July 01, 2018

Robust low-volume production of nanoparticles for genetic manipulation of cells

Read More PDF

Application Note

July 01, 2018

Seamless scale up of liposomal verteporfin formulations using the NanoAssemblr™ Platform

Read More PDF

Publication - Abstract

April 26, 2018

Small Methods

State‐of‐the‐Art Design and Rapid‐Mixing Production Techniques of Lipid Nanoparticles for Nucleic Acid Delivery

Evers, M. J. W., Kulkarni, J. A., van der Meel, R., Cullis, P. R., Vader, P., & Schiffelers, R. M.

Read More

Publication - Abstract

February 27, 2018

Cell Reports

A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing

J. Finn, A. Smith, M. Patel, L. Shaw, M. Youniss, J. Heteren, T. Dirstine, C. Ciullo, R. Lescarbeau, J. Seitzer, R. Shah...

Read More


August 04, 2018

Microfluidic Manufacture of PLGA Nano and Microparticle Drug Delivery Vehicles

Read More PDF


August 01, 2018

Microfluidics-based Manufacture of PEG-b-PLGA Block Copolymer Nanoparticles for the Delivery of Small Molecule Therapeutics

Read More PDF
Resource Center

Stay Informed

Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.